Asymchem, Inc.

A USFDA-inspected CDMO experienced in developing sustainable processes for late phase to commercial small molecule and peptide APIs with a proven track record of taking projects from development to commercial scale. Founded in 1995, Asymchem has 7 sites across P.R. China and an enabling technology platform in continuous flow and biocatalysis, with a specialized facility for the development and GMP manufacture of HPAPI, including cytotoxic and β-lactams.  Capabilities and experience in hazardous chemistry applications includes ozonolysis, hydrogenation, and other high temperature and high-pressure reactions. Asymchem has a research group dedicated to process optimization, process design space characterization (PAR/NOR), and manufacturing of peptides and peptide-containing drugs.